Dr Obermayer-Pietsch has received travel grants and research support from Eli Lilly and Company. Dr Boonen has received research support from Eli Lilly and Company. Dr Fraser has received an unrestricted educational grant and honoraria from Eli Lilly and Company. Dr Hadji has received travel grants, speaker's honoraria, and consultancy fees from Eli Lilly and Company. Dr McCloskey has received research support and speaker's fees from Eli Lilly and Company. Drs Marin, Barker, and Nickelsen are full-time employees of Eli Lilly and Company. All other authors state that they have no conflicts of interest.
Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment†
Version of Record online: 19 MAY 2008
Copyright © 2008 ASBMR
Journal of Bone and Mineral Research
Volume 23, Issue 10, pages 1591–1600, October 2008
How to Cite
Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., Hadji, P., Farrerons, J., Boonen, S., Audran, M., Barker, C., Anastasilakis, A. D., Fraser, W. D. and Nickelsen, T. (2008), Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment. J Bone Miner Res, 23: 1591–1600. doi: 10.1359/jbmr.080506
Preliminary data for this article were presented previously at the 28th Annual Meeting of the American Society for Bone and Mineral Research, September 15–19, 2006, Philadelphia, PA, USA, and at the 7th Annual Meeting of the European Congress on Clinical and Economic Aspects of Osteoporosis, March 28–31, 2007, Porto, Portugal.
- Issue online: 4 DEC 2009
- Version of Record online: 19 MAY 2008
- Manuscript Accepted: 12 MAY 2008
- Manuscript Revised: 30 APR 2008
- Manuscript Received: 5 MAR 2008
- 82004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745–751., , ,Direct Link:
- 131999 Parathyroid hormone 1-34 [hPTH 1-34] and estrogen produce dramatic bone density increases in postmenopausal osteoporosis: Results from a placebo-controlled randomized trial. J Bone Miner Res 14: S1; S137., , , , , ,
- 15National Institute for Health and Clinical Excellence 2005 Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE Technology Appraisal 87, January 2005. Available online at http://www.nice.org.uk/TA087guidance. Accessed September 8, 2007.
- 242001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16: 157–165., , , , ,
- 30Eli Lilly and Co 2004 FORTEO [package insert] Eli Lilly and Co, Indianapolis, IN, USA.
- 31for the EUROFORS High Resolution Quantitative Computed Tomography Substudy Group 2007 Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study. J Bone Miner Res 22: 1426–1433., , , , , , ,